The concern of generic rivalry has repeatedly loomed around copyright’s iconic drug, Viagra, sparking questions about the future of related drug holdings. While first years saw significant profits, the patent expiration has allowed the path for less expensive substitutes, possibly diminishing earnings and presenting a genuine danger for sharehold